Immunocore Holdings plc (NASDAQ:IMCR – Get Rating)’s stock price gapped down before the market opened on Friday . The stock had previously closed at $27.46, but opened at $26.67. Immunocore shares last traded at $27.65, with a volume of 803 shares trading hands.
Several equities research analysts have issued reports on IMCR shares. Zacks Investment Research upgraded Immunocore from a “hold” rating to a “buy” rating and set a $38.00 price objective on the stock in a report on Thursday, May 5th. HC Wainwright started coverage on Immunocore in a report on Tuesday, February 8th. They set a “buy” rating and a $80.00 price objective on the stock.
The company has a current ratio of 4.58, a quick ratio of 4.57 and a debt-to-equity ratio of 0.39. The stock has a 50-day simple moving average of $31.77 and a 200-day simple moving average of $29.80. The company has a market cap of $1.21 billion, a price-to-earnings ratio of -7.46 and a beta of 0.43.
Several institutional investors and hedge funds have recently bought and sold shares of IMCR. Rockefeller Capital Management L.P. acquired a new position in Immunocore during the fourth quarter valued at $34,000. Royal Bank of Canada acquired a new position in Immunocore during the first quarter valued at $79,000. Morgan Stanley raised its position in Immunocore by 11,505.0% during the third quarter. Morgan Stanley now owns 2,321 shares of the company’s stock valued at $86,000 after buying an additional 2,301 shares during the period. Bank of America Corp DE grew its stake in Immunocore by 57.9% in the fourth quarter. Bank of America Corp DE now owns 3,558 shares of the company’s stock valued at $121,000 after purchasing an additional 1,305 shares in the last quarter. Finally, Sphera Funds Management LTD. purchased a new position in Immunocore in the third quarter valued at about $157,000. 51.16% of the stock is currently owned by institutional investors.
Immunocore Company Profile (NASDAQ:IMCR)
Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. Its other programs for oncology comprise IMC-C103C that is in Phase I/II dose escalation trial in patients with solid tumor cancers, including non-small-cell lung (NSCLC), gastric, head and neck, ovarian, and synovial sarcoma cancers; IMC-F106C, which is in a Phase I/II dose escalation trial in patients with multiple solid tumor cancers comprising NSCLC, small-cell lung, endometrial, ovarian, cutaneous melanoma, and breast cancers.
- Get a free copy of the StockNews.com research report on Immunocore (IMCR)
- Short Sellers Provide Entry Into Hibbet, Inc At Rock Bottom Prices
- Affirm Stock Has Affirmed a Bottom
- Airbnb: Bold Competitive Threats & A New World of Travel
- Is RBC Bearings Rolling Into A Reversal?
- Should Dollar General or Dollar Tree Give Investors a Case of FOMO?
Receive News & Ratings for Immunocore Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunocore and related companies with MarketBeat.com's FREE daily email newsletter.